Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Crawford on Abiraterone Versus Enzalutamide in Prostate Cancer

E. David Crawford, MD
Published: Saturday, Mar 19, 2016



E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting treatment with abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with castration-resistant prostate cancer (CRPC).

There are several factors that influence this decision, Crawford explains. For example, it depends whether patients have previously received anti-androgen therapies or agents such as ketoconazole. Crawford uses both enzalutamide and abiraterone in clinical practice, as well as studies the results of clinical trials investigating both therapies.

Further research is needed on whether using enzalutamide and abiraterone in combination demonstrates strong efficacy in these patients, Crawford adds.

<<< View more from 2016 New York GU



E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses factors in selecting treatment with abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with castration-resistant prostate cancer (CRPC).

There are several factors that influence this decision, Crawford explains. For example, it depends whether patients have previously received anti-androgen therapies or agents such as ketoconazole. Crawford uses both enzalutamide and abiraterone in clinical practice, as well as studies the results of clinical trials investigating both therapies.

Further research is needed on whether using enzalutamide and abiraterone in combination demonstrates strong efficacy in these patients, Crawford adds.

<<< View more from 2016 New York GU


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x